Login to Your Account

Trevi raises $50.5 million series C, led by NEA

By Michael Fitzhugh
Staff Writer

Thursday, July 20, 2017

Trevi Therapeutics Inc. said a new $50.5 million series C financing led by New Enterprise Associates will help it advance the development of Nalbuphine ER, a twice-daily oral opioid in development for the treatment of two forms of severe itching.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription